The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad285 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, 2024. Verfasst von Christina Vivelo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Neoplasms, Biomedical Research. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCI NIH HHS, CCR NIH HHS.
Abstract (Originalsprache)
Rare cancers and other rare nonmalignant tumors comprise 25% of all cancer diagnoses and account for 25% of all cancer deaths. They are difficult to study due to many factors, including infrequent occurrence, lack of a universal infrastructure for data and/or tissue collection, and a paucity of disease models to test potential treatments. For each individual rare cancer, the limited number of diagnosed cases makes it difficult to recruit sufficient patients for clinical studies, and rare cancer research studies are often siloed. As a result, progress has been slow for many of these cancers. While rare cancer research efforts have increased over time, the breadth of the research landscape is not known. A recent literature search revealed a sharp increase in rare tumor, and rare cancer publications began in the early 2000s. To identify rare cancer research efforts being conducted in the US and globally, we conducted an online search of rare tumor/rare cancer research programs and identified 76 programs. To gain a deeper understanding of these programs, we composed and conducted a survey to ask programs for details about their research efforts. Of the 42 programs contacted to complete the survey, 23 programs responded. Survey results show most programs are collecting clinical data, molecular data, and biospecimens, and many are conducting molecular analyses. This landscape analysis demonstrates that multiple rare cancer research efforts are ongoing, and the rare cancer community may benefit from collaboration among stakeholders to accelerate research and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Kelly Government Systems, Bethesda, MD, USA.
- Broad Institute, Cambridge, MA, USA.
- Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders, Center and Harvard Medical School, Department of Pediatric Oncology, Boston, MA, USA.
- Department of Neurology, Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, CA, USA.
- Caryl and Israel Englander Institute for Precision Medicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
ORCID-Profile: Abby B Sandler
Förderung
- NIDA NIH HHS
- NCI NIH HHS
- CCR NIH HHS
- Intramural NIH HHS
- Cancer Moonshot
- My Pediatric and Adult Rare Tumor Network
- Center for Cancer Research
- National Cancer Institute
Zitieren
APA
Vivelo, C., Reilly, K. M., Widemann, B. C., Wedekind, M. F., Painter, C., O'Neill, A. F., Mueller, S., Elemento, O., Gross, A. M., & Sandler, A. B. (2024). The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. The Oncologist. https://doi.org/10.1093/oncolo/oyad285
Vancouver
Vivelo C, Reilly KM, Widemann BC, Wedekind MF, Painter C, O'Neill AF, et al. The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review. The Oncologist. 2024. doi:10.1093/oncolo/oyad285
BibTeX
@article{Vivelo2024,
author = {Vivelo, Christina and Reilly, Karlyne M and Widemann, Brigitte C and Wedekind, Mary Frances and Painter, Corrie and O'Neill, Allison F and Mueller, Sabine and Elemento, Olivier and Gross, Andrea M and Sandler, Abby B},
title = {The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad285}
}
EUVIMED